在自身炎症性干扰病和单源性全身性红血性狼中出现的新概念和治疗方法
Raphaela Goldbach-Mansky1, Sara Alehashemi2, Adriana A de Jesus2
1Translational Autoinflammatory Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. goldbacr@mail.nih.gov.
Nature reviews. Rheumatology
|December 2, 2024
概括
基因定义的自身炎症性干扰病正在增加,与核酸和蛋白质加工缺陷有关. 了解这些干扰素通路可以揭示新的个性化治疗目标.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 类风湿病学 类风湿病学
背景情况:
- 在过去的20年中,基因定义的自身炎症性干扰性疾病增加了.
- 艾卡迪-古提耶氏综合征和蛋白酶相关的自身炎症综合征 (PRAAS) 涉及受损的核酸/蛋白质处理.
- 这些通路的缺陷会通过细胞内传感器激活I型干扰素的产生.
研究的目的:
- 引入对自身炎症性干扰性疾病的分类.
- 讨论干扰素生产和信号传递的共享和分歧的病理机制.
- 为个性化治疗确定新的药物标.
主要方法:
- 对导致自身炎症性干扰性病变的遗传缺陷的审查.
- 细胞内传感器和干扰素信号通路的分析.
- 自发炎性干扰病与单一性SLE的比较.
主要成果:
- 核酸/蛋白质加工过程中的遗传缺陷导致I型干扰症.
- 激活STING会导致SAVI/COPA综合征中的肺炎;受体信号突变会导致中枢神经系统问题.
- 单一性SLE涉及对细胞外核酸的自身抗体,使其与干扰性疾病区别开来.
结论:
- 建议对自身炎症性干扰性疾病进行分类.
- 讨论了干扰素生产/信号的共同和独特机制.
- 基于新的见解,针对个性化治疗的新药标正在出现.
相关概念视频
Autoimmune Disorders
386
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
386
Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
T Cell Types and Functions
951
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
951
What is the Immune System?
110.3K
Overview
110.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142


